- Previous Close
12.65 - Open
12.28 - Bid 11.87 x 100
- Ask 12.10 x 200
- Day's Range
11.31 - 12.61 - 52 Week Range
11.31 - 27.20 - Volume
1,938,777 - Avg. Volume
970,910 - Market Cap (intraday)
977.005M - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
-- - EPS (TTM)
-3.07 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
39.69
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also offers VRDN-006 that is in Phase 1 clinical trial and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
www.viridiantherapeutics.comRecent News: VRDN
View MorePerformance Overview: VRDN
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRDN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRDN
View MoreValuation Measures
Market Cap
978.63M
Enterprise Value
471.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.70k
Price/Book (mrq)
2.03
Enterprise Value/Revenue
1.56k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.32%
Return on Equity (ttm)
-48.48%
Revenue (ttm)
302k
Net Income Avi to Common (ttm)
-208.56M
Diluted EPS (ttm)
-3.07
Balance Sheet and Cash Flow
Total Cash (mrq)
717.58M
Total Debt/Equity (mrq)
3.44%
Levered Free Cash Flow (ttm)
-136.82M